Navigation Links
Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008
Date:2/19/2009

485 512,352 Litigation settlements, net 16,537 (1,171) 16,634 (5,946) ------ ------ ------ ------ Total operating expenses 360,062 1,624,334 1,772,336 2,105,353 ------- --------- --------- --------- Earnings (loss) from operations 34,591 (1,268,236) 297,885 (996,058) Interest expense 92,256 133,383 357,045 200,394 Other (expense) income, net (9,246) (43,863) 11,337 97,060 ------ ------- ------ ------ (Loss) earnings before income taxes and minority interest (66,911) (1,445,482) (47,823) (1,099,392) Income tax (benefit) provision (59,955) (77,632) 137,423 112,823 ------- ------- ------- ------- Loss before minority interest (6,956) (1,367,850) (185,246) (1,212,215) Minority interest income (1,765) (272) (4,031) (2,901) ------ ---- ------ ------ Net loss before preferred dividends (5,191) (1,367,578) (181,215) (1,209,314) Preferred dividends 34,799 15,999 139,035 15,999 ------ ------ ------- ------ Net loss available to common shareholders $(39,990) $(1,383,577) $(320,250) $(1,225,313) ======== =========== ========= =========== Loss per common share: Basic
'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Mylan Announces Pricing of Tender Offers for its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015
2. Mylan to Host Investor Day on October 3, 2007
3. Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD
4. Mylan Announces Appointment of Steven G. Zylstra as Vice President of Global Corporate Communication and Public Relations
5. Mylan Announces Tentative FDA Approval for Lamotrigine Tablets
6. Mylan Announces Final FDA Approval for Balsalazide Disodium Capsules
7. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
8. Mylan Announces Final FDA Approval for Ropinirole Hydrochloride Tablets
9. Mylan Launches First Generic Version of Antihypertensive Sular(R) ER in the United States
10. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
11. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014 According to a new ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... at USD 88.5 million in 2011, which is expected ... a CAGR of 53.8% from 2013 to 2023. ... http://www.transparencymarketresearch.com/quantum-dots.html Increasing demand for energy efficient ...
(Date:7/31/2014)... , July 31, 2014 Research and ... "Global Genomics Market 2014-2018" report to their offering. ... Genomics is the study of the genetic material or ... a strong basis for the discovery and development of ... diseases or health conditions. Genomics is supported by three ...
(Date:7/31/2014)... San Francisco, Calif. (PRWEB) July 31, 2014 ... provides newly diagnosed patients with an overview of the ... the management of drug side effects, as well as ... , “We’re grateful to Dr. Sandy Srinivas for organizing ... 25-year survivor of kidney cancer. “Sandy and her colleagues ...
(Date:7/31/2014)... BOTHELL, Wash. , July 31, 2014   ... a leading developer, manufacturer and marketer of proprietary clinical ... media and precision thermal shipping products ... Company,s second quarter 2014 financial results will be released ... will host a conference call and live webcast at ...
Breaking Biology Technology:Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 2Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 3Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 4Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2BioLife Solutions to Report Financial Results for Second Quarter 2014 and Provide Business Update on August 7, 2014 2
... Trial of Novel Antidepressant,Tyrima(TM) and Advancement of Cannabinoid ... 17 CeNeRx BioPharma,Inc., a clinical stage company ... central nervous system (CNS), today,announced completion of a ... L Capital Partners and Pappas Ventures,participated in the ...
... Penn State and the University of Texas Southwestern Medical Center ... proteins that catalyze biochemical reactions. "This is one of ... a protein using light," said Stephen Benkovic, Penn State Evan ... in Chemistry, and one of the team,s leaders. "The ...
... SAN DIEGO, Oct. 16 Anadys Pharmaceuticals,Inc. (Nasdaq: ... quarter 2008,financial results on Thursday, October 23, 2008, after ... conference call and webcast to discuss its third,quarter 2008 ... on,its development programs on Thursday, October 23, 2008 at ...
Cached Biology Technology:CeNeRx BioPharma Completes $15 Million Series B Financing 2CeNeRx BioPharma Completes $15 Million Series B Financing 3CeNeRx BioPharma Completes $15 Million Series B Financing 4Scientists use light to control proteins 2Anadys Pharmaceuticals to Report Third Quarter 2008 Financial Results 2
(Date:7/31/2014)... --- By tracing nearly 3,000 genes to the ... of Florida scientists have created an extensive "Tree ... large-scale, next-generation DNA sequencing. , Among the ... related to small moths than to large ones, ... evolved. The study also found that some insects ...
(Date:7/31/2014)... hazard lurks beneath many of the roughly 156,000 ... hazard is corrosion in parts of underground gas ... and contamination of groundwater, a source of drinking ... states have reported many rapidly corroding gas storage ... are generally associated with use of gasoline-ethanol blends ...
(Date:7/31/2014)... people make a rational choice to be liberal or ... it a matter of genetics?, Two political scientists from ... University say that neither conscious decision-making nor parental upbringing ... lean right. , A growing body of evidence shows ... core of political differences, the researchers say in the ...
Breaking Biology News(10 mins):UF study advances 'DNA revolution,' tells butterflies' evolutionary history 2UF study advances 'DNA revolution,' tells butterflies' evolutionary history 3NIST corrosion lab tests suggest need for underground gas tank retrofits 2Scientists find growing consensus: Political attitudes derive from body and mind 2
... REDWOOD SHORES, Calif., Aug. 14 (OTC Bulletin,Board: ... leading supplier of electronic signature solutions for,business process ... in biometric signature verification, announced today its financial,results ... 30, 2008., Total revenues for the three ...
... in Hawaii, but flying balloons over a volcano usually isn,t ... Durant, an adjunct geological sciences faculty member at Michigan ... volcano this summer to make the first on-location measurements of ... the volcano. The Kilauea volcano began erupting in March. ...
... for what causes a debilitating shell disease affecting lobsters ... Marine Biological Laboratory (MBL) visiting scientist to suspect environmental ... plastics. Preliminary evidence from the lab of ... be interfering with the ability of lobsters to develop ...
Cached Biology News:Communication Intelligence Corporation Reports Second Quarter 2008 Financial Results 2Communication Intelligence Corporation Reports Second Quarter 2008 Financial Results 3Communication Intelligence Corporation Reports Second Quarter 2008 Financial Results 4Communication Intelligence Corporation Reports Second Quarter 2008 Financial Results 5Communication Intelligence Corporation Reports Second Quarter 2008 Financial Results 6Studying volcanoes with balloons 2Studying volcanoes with balloons 3Plastics suspect in lobster illness 2
... APAgene kits are designed to rapidly ... using our patented APA Technology. APAgene provides ... competitive price. All necessary ingredients are provided ... can be used for gap filling, localized ...
Rabbit polyclonal to Yaf9 ( Abpromise for all tested applications)....
... Serum; U.S. sourced, ideal for ... quality; Low hemoglobin; Endotoxin: < ... of US origin; U.S. sourced, ... an uncompromising quality. Low hemoglobin ...
...
Biology Products: